Skip to main
BLTE
BLTE logo

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc. is positioned for potential share appreciation over the next 12-18 months, primarily driven by anticipated updates regarding the Phase 3 clinical trials for its lead product, tinlarebant, targeting untreatable eye diseases. The company has demonstrated a solid cash position and an increased sample size for its Phase 3 PHOENIX trial, with strong enrollment figures, indicating robust investor interest following recent interim analysis updates. Additionally, the positive preliminary data from the Phase 2 studies and the heightened estimated pricing for tinlarebant suggest significant growth potential as the company aims to secure FDA approval for its treatments targeting eye diseases such as STGD1.

Bears say

Belite Bio Inc reported a significant net loss of $36.1 million in 2024, raising concerns regarding its financial sustainability amid ongoing clinical trials. The company faces substantial risks related to its drug candidate, tinlarebant, which include potential failures in clinical trials and regulatory approval that could hinder its path to commercialization in a competitive market. Furthermore, ongoing regulatory processes and the possibility of equity dilution add to the uncertainties surrounding the company’s financial outlook and viability.

BLTE has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Strong Buy based on their latest research and market trends.

According to 5 analysts, BLTE has a Strong Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.